Evidence map›Paper›PMID 38529118›Full record

ArticleFrontiers in medicine2024

Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation.

Hiam Chemaitelly, Houssein H Ayoub, Patrick Tang, Hadi M Yassine, Asmaa A Al Thani, Mohammad R Hasan, Peter Coyle, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko and 12 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Hiam ChemaitellyInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Houssein H AyoubMathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
Patrick TangDepartment of Pathology, Sidra Medicine, Doha, Qatar.
Hadi M YassineBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Asmaa A Al ThaniBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Mohammad R HasanDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Peter CoyleBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Zaina Al-KanaaniHamad Medical Corporation, Doha, Qatar.
Einas Al-KuwariHamad Medical Corporation, Doha, Qatar.
Andrew JeremijenkoHamad Medical Corporation, Doha, Qatar.
Anvar Hassan KaleeckalHamad Medical Corporation, Doha, Qatar.
Ali Nizar LatifHamad Medical Corporation, Doha, Qatar.
Riyazuddin Mohammad ShaikHamad Medical Corporation, Doha, Qatar.
Hanan F Abdul-RahimDepartment of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Gheyath K NasrallahBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Mohamed Ghaith Al-KuwariPrimary Health Care Corporation, Doha, Qatar.
Adeel A ButtDepartment of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, United States.
Hamad Eid Al-RomaihiMinistry of Public Health, Doha, Qatar.
Mohamed H Al-ThaniMinistry of Public Health, Doha, Qatar.
Abdullatif Al-KhalHamad Medical Corporation, Doha, Qatar.
Roberto BertolliniMinistry of Public Health, Doha, Qatar.
Laith J Abu-RaddadInfectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Reinfections are increasingly becoming a feature in the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, accurately defining reinfection poses methodological challenges. Conventionally, reinfection is defined as a positive test occurring at least 90 days after a previous infection diagnosis. Yet, this extended time window may lead to an underestimation of reinfection occurrences. This study investigated the prospect of adopting an alternative, shorter time window for defining reinfection. Methods: A longitudinal study was conducted to assess the incidence of reinfections in the total population of Qatar, from February 28, 2020 to November 20, 2023. The assessment considered a range of time windows for defining reinfection, spanning from 1 day to 180 days. Subgroup analyses comparing first versus repeat reinfections and a sensitivity analysis, focusing exclusively on individuals who underwent frequent testing, were performed. Results: The relationship between the number of reinfections in the population and the duration of the time window used to define reinfection revealed two distinct dynamical domains. Within the initial 15 days post-infection diagnosis, almost all positive tests for SARS-CoV-2 were attributed to the original infection. However, surpassing the 30-day post-infection threshold, nearly all positive tests were attributed to reinfections. A 40-day time window emerged as a sufficiently conservative definition for reinfection. By setting the time window at 40 days, the estimated number of reinfections in the population increased from 84,565 to 88,384, compared to the 90-day time window. The maximum observed reinfections were 6 and 4 for the 40-day and 90-day time windows, respectively. The 40-day time window was appropriate for defining reinfection, irrespective of whether it was the first, second, third, or fourth occurrence. The sensitivity analysis, confined to high testers exclusively, replicated similar patterns and results. Discussion: A 40-day time window is optimal for defining reinfection, providing an informed alternative to the conventional 90-day time window. Reinfections are prevalent, with some individuals experiencing multiple instances since the onset of the pandemic.

Indexed as

biasCOVID-19epidemiologyimmunityreinfectiontime window

Identifiers

PMID38529118
PMCPMC10961414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.